Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2015

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

Résumé

The optimal management of patients with relapsed chronic lymphocytic leukemia (CLL) is dictated by the type of prior therapy, duration of prior response, presence of genomic aberrations, age, and comorbidities. The patterns of relapses and the clinical outcomes of second-line options after fludarabine-cyclophosphamide-rituximab (FCR) is given as a frontline treatment are currently unknown. In this retrospective and non-randomized study, we report the outcomes of 132 patients from databases of 14 French CLL study group centers who needed a second-line treatment after FCR frontline. Bendamustine + rituximab (BR) was the most frequently used second-line regimen, followed by alemtuzumab-based regimens, R-CHOP, and FCR. Median progression-free survival (PFS) was 18 months after BR with a median overall survival (OS) not reached. We also found that response durations of < 36 months and the presence of del(17p) are critical factors that contribute to poor overall survival. BR appears to be an effective salvage regimen in our series, both in terms of progression-free and overall survival. Patients who relapsed less than 36 months after FCR have a poor outcome, not significantly different in this study from patients with early relapses less than 12 or 24 months.

Dates et versions

hal-01684650 , version 1 (15-01-2018)

Identifiants

Citer

Luc-Matthieu Fornecker, Thérèse Aurran-Schleinitz, Anne-Sophie Michallet, Bruno Cazin, Romain Guiéze, et al.. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience. American Journal of Hematology, 2015, 90 (6), pp.511 - 514. ⟨10.1002/ajh.23999⟩. ⟨hal-01684650⟩
93 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More